Merck Sees $1.13M in Bullish Call Activity as Stock Approaches 52-Week High

By TrendSpider Editor

Unusual options activity in Merck & Company, Inc. is drawing attention Thursday, with two large call contracts totaling $1,130,000 in combined premium hitting the tape as MRK trades at $152.28, up 0.37% on the session. Both contracts target the $155 strike expiring October 16, 2026, suggesting trade

Merck Sees $1.13M in Bullish Call Activity as Stock Approaches 52-Week High

Unusual options activity in Merck & Company, Inc. is drawing attention Thursday, with two large call contracts totaling $1,130,000 in combined premium hitting the tape as MRK trades at $152.28, up 0.37% on the session. Both contracts target the $155 strike expiring October 16, 2026, suggesting traders are positioning for a continued push higher over the next six weeks. With the stock trading near the upper end of its 52-week range of $77.58 to $156.92, the bullish flow carries notable conviction given how little room remains before all-time highs are tested.

Key Drivers of the MRK Stock Move

• Main Catalyst: Two call contracts on the $155 strike expiring October 16, 2026 printed with a combined volume of 2,500 contracts and $1,130,000 in total premium. The first block of 1,000 contracts carried $452,000 in premium, while a second block of 1,500 contracts added $678,000, both out of the money relative to the current price of $152.28.
• Bull Case: The second contract printed at 97% of open interest, signaling an aggressive new position rather than a hedge against existing holdings. With MRK already up more than 96% from its 52-week low of $77.58 and trading within roughly $5 of the $155 strike, the options buyer needs only a modest move of about 1.8% for these calls to move into the money before expiration.
• Bear Case: Both strikes sit out of the money, meaning the full $1,130,000 in premium is at risk if MRK fails to clear $155 by October 16, 2026. The stock is also pressing against its 52-week high of $156.92, a level that represents significant technical resistance and could cap near-term upside even if sentiment remains positive.

The forward setup for MRK is constructive given the proximity to its 52-week high, and the concentration of premium in a single near-dated strike suggests the options buyer expects a defined near-term catalyst rather than a slow grind higher. The six-week window to the October 16 expiration is tight, placing added importance on any company announcements, pipeline updates, or broader pharmaceutical sector developments that could serve as the trigger this trade requires. Traders should watch the $155 level closely as both a potential breakout point and a natural area of resistance heading into the back half of the third quarter.

MRK Unusual Options Activity

• Contract 1: Call, $155 strike, expiring October 16, 2026 | Volume: 1,000 | Open Interest: 64% | Premium: $452,000 | Out of the money
• Contract 2: Call, $155 strike, expiring October 16, 2026 | Volume: 1,500 | Open Interest: 97% | Premium: $678,000 | Out of the money

Total unusual contracts flagged: 2. Total combined premium: $1,130,000. Both contracts share the same strike and expiration, reinforcing a concentrated directional bet rather than a spread or hedging strategy. The second block printing at 97% of open interest is the more aggressive signal of the two.

MRK Seasonality

The early September through mid-October window has historically coincided with increased pharmaceutical sector volatility as companies approach Q3 earnings season and key medical conference schedules. An October 16 expiration places this trade squarely in the zone where pipeline or commercial updates could serve as a near-term price catalyst for MRK.

MRK Relative Performance

MRK's current price of $152.28 represents a gain of more than 96% from its 52-week low of $77.58, a recovery that significantly outpaces many large-cap pharmaceutical peers that have faced pipeline setbacks or pricing headwinds over the same period. Trading within approximately 3% of its 52-week high of $156.92, MRK is one of the stronger-performing names in the large-cap pharma space on a trailing 52-week basis, which adds credibility to the bullish options positioning seen today.